IgA nephropathy

News

Vertex chief executive Reshma Kewalramani

Vertex preps FDA filing for IgAN drug after phase 3 readout

Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.

News

Otsuka joins IgAN market with Voyxact approval in US

Otsuka has claimed FDA approval for its IgAN therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch.

News

Chugai buys 'Asia lag' firm Renalys for $98m upfront

Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia.

News

Otsuka, Vera stake their claims to IgAN treatment

Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?

News

NICE relents and backs drug for IgAN from CSL Vifor

Thousands of people living with rare kidney disease IgAN in the UK will soon be able to access a new oral treatment from CSL Vifor.

News

Novartis gets FDA nod for second of three IgAN drugs

Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy.

Vertex preps FDA filing for IgAN drug after phase 3 readout

Otsuka joins IgAN market with Voyxact approval in US

Chugai buys 'Asia lag' firm Renalys for $98m upfront

Otsuka, Vera stake their claims to IgAN treatment

NICE relents and backs drug for IgAN from CSL Vifor

Novartis gets FDA nod for second of three IgAN drugs

After setback, Rhythm gets good news on Imcivree from FDA

Using AI-driven synthetic personas to take your insights fur...

IgA nephropathy

Editor's Picks